{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:35Z","timestamp":1791414155201,"version":"4.3.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Federal Ministry of Education and Research","award":["01ZX1905A"],"award-info":[{"award-number":["01ZX1905A"]}]},{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Immune checkpoint inhibitor (ICI) therapies effectively treat a broadening spectrum of cancer entities but induce various immune-related side effects (irAEs). Recent reports suggest a correlation between ICI-induced systemic inflammation and thromboembolic events as\u00a0well as an increased effectiveness by coadministration of\u00a0anticoagulants. With cancer patients having a higher risk of thrombotic events per se, it is crucial to dissect and characterize the mechanisms that cause pro-coagulative effects induced\u00a0by systemic tumor therapies and their potential interplay with anti-tumor response. A total of 31 patients with advanced skin cancer treated with either ICIs (<jats:italic>n<\/jats:italic>\u2009=\u200924) or BRAF\/MEK inhibitors (<jats:italic>n<\/jats:italic>\u2009=\u20097) were longitudinally assessed for blood and coagulation parameters before as well as 7, 20 and 40 days after initiation of systemic tumor\u00a0therapy. Changes were analyzed and compared between both groups. In addition, the influence of coagulation parameters on progression-free, recurrence-free and overall survival was investigated. The ICI cohort presented significantly increased factor VIII activity after one week of therapy (<jats:italic>p<\/jats:italic> 0.0225); while, protein S activity was reduced during the whole observation period. Additionally, von Willebrand factor activity and tissue factor concentrations increased under immunotherapy. Similar changes occurred under BRAF\/MEK inhibitor therapy (BRAF\/MEKi). Increased baseline levels of von Willebrand factor antigen and factor VIII:C before the start of ICI therapy correlated with a significantly higher risk of recurrence for patients receiving adjuvant\u00a0immunotherapy. The findings suggest the induction of a pro-coagulant state under ICI and BRAF\/MEKi and a role of coagulation parameters in the efficacy of ICI therapies.<\/jats:p>","DOI":"10.1007\/s00262-024-03850-y","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T09:03:00Z","timestamp":1730538180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Interdependence of coagulation with immunotherapy and BRAF\/MEK inhibitor therapy: results from a prospective study"],"prefix":"10.1007","volume":"74","author":[{"given":"Malte","family":"Beckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Schl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Hackstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"3850_CR1","doi-asserted-by":"publisher","first-page":"CD011123","DOI":"10.1002\/14651858.CD011123.pub2","volume":"2","author":"S Pasquali","year":"2018","unstructured":"Pasquali S, Hadjinicolaou AV, Chiarion Sileni V et al (2018) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2:CD011123. https:\/\/doi.org\/10.1002\/14651858.CD011123.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3850_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5:1008\u20131019. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"},{"key":"3850_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","volume":"147","author":"R Kramer","year":"2021","unstructured":"Kramer R, Zaremba A, Moreira A et al (2021) Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer 147:170\u2013181. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.013","journal-title":"Eur J Cancer"},{"key":"3850_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051985","author":"L Diaz","year":"2023","unstructured":"Diaz L, Jauzelon B, Dillies A-C et al (2023) Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12051985","journal-title":"J Clin Med"},{"key":"3850_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21670","volume":"14","author":"W Kida","year":"2022","unstructured":"Kida W, Nakaya M, Ito A et al (2022) A case of acquired factor v inhibitor following nivolumab administration. Cureus 14:e21670. https:\/\/doi.org\/10.7759\/cureus.21670","journal-title":"Cureus"},{"key":"3850_CR6","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.jtho.2018.06.024","volume":"13","author":"R Kato","year":"2018","unstructured":"Kato R, Hayashi H, Sano K et al (2018) Nivolumab-induced hemophilia a presenting as gastric ulcer bleeding in a patient with NSCLC. J Thorac Oncol 13:e239\u2013e241. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.024","journal-title":"J Thorac Oncol"},{"key":"3850_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejca.2017.11.018","volume":"91","author":"C Boutros","year":"2018","unstructured":"Boutros C, Scoazec J-Y, Mateus C et al (2018) Arterial thrombosis and anti-PD-1 blockade. Eur J Cancer 91:164\u2013166. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.018","journal-title":"Eur J Cancer"},{"key":"3850_CR8","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/1759-7714.12872","volume":"9","author":"T Ikeda","year":"2018","unstructured":"Ikeda T, Yamaguchi H, Dotsu Y et al (2018) Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. Thorac Cancer 9:1522\u20131524. https:\/\/doi.org\/10.1111\/1759-7714.12872","journal-title":"Thorac Cancer"},{"key":"3850_CR9","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/eji.201847645","volume":"48","author":"Y Horio","year":"2018","unstructured":"Horio Y, Takamatsu K, Tamanoi D et al (2018) Trousseau\u2019s syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient. Eur J Immunol 48:1764\u20131767. https:\/\/doi.org\/10.1002\/eji.201847645","journal-title":"Eur J Immunol"},{"key":"3850_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","volume":"158","author":"J Gong","year":"2021","unstructured":"Gong J, Drobni ZD, Alvi RM et al (2021) Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer 158:99\u2013110. https:\/\/doi.org\/10.1016\/j.ejca.2021.09.010","journal-title":"Eur J Cancer"},{"key":"3850_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060762","author":"R Sato","year":"2019","unstructured":"Sato R, Imamura K, Sakata S et al (2019) Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8060762","journal-title":"J Clin Med"},{"key":"3850_CR12","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J et al (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142:2299\u20132311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049981","journal-title":"Circulation"},{"key":"3850_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L, Eigentler TK, Fluck M et al (2019) Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4:e000491. https:\/\/doi.org\/10.1136\/esmoopen-2019-000491","journal-title":"ESMO Open"},{"key":"3850_CR14","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1002\/cam4.3938","volume":"10","author":"A Guha","year":"2021","unstructured":"Guha A, Jain P, Fradley MG et al (2021) Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries. Cancer Med 10:3862\u20133872. https:\/\/doi.org\/10.1002\/cam4.3938","journal-title":"Cancer Med"},{"key":"3850_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi BB, Reiner AS, Kamel H et al (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70:926\u2013938. https:\/\/doi.org\/10.1016\/j.jacc.2017.06.047","journal-title":"J Am Coll Cardiol"},{"key":"3850_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 160:809. https:\/\/doi.org\/10.1001\/archinte.160.6.809","journal-title":"Arch Intern Med"},{"key":"3850_CR17","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137:1959\u20131969. https:\/\/doi.org\/10.1182\/blood.2020007338","journal-title":"Blood"},{"key":"3850_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","volume":"225","author":"AS Kim","year":"2020","unstructured":"Kim AS, Khorana AA, McCrae KR (2020) Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res 225:33\u201353. https:\/\/doi.org\/10.1016\/j.trsl.2020.06.012","journal-title":"Transl Res"},{"key":"3850_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","volume":"13","author":"SH Tay","year":"2022","unstructured":"Tay SH, Toh MMX, Thian YL et al (2022) Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol 13:807050. https:\/\/doi.org\/10.3389\/fimmu.2022.807050","journal-title":"Front Immunol"},{"key":"3850_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/CMR.0000000000000599","volume":"29","author":"AG Mackin","year":"2019","unstructured":"Mackin AG, Pecen PE, Dinsmore AL et al (2019) Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res 29:522\u2013526. https:\/\/doi.org\/10.1097\/CMR.0000000000000599","journal-title":"Melanoma Res"},{"key":"3850_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","volume":"23","author":"DJ Lee","year":"2021","unstructured":"Lee DJ, Lee HJ, Farmer JR et al (2021) Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep 23:98. https:\/\/doi.org\/10.1007\/s11886-021-01530-2","journal-title":"Curr Cardiol Rep"},{"issue":"Suppl_5","key":"3850_CR22","doi-asserted-by":"publisher","first-page":"S867","DOI":"10.1016\/annonc\/annonc706","volume":"32","author":"JS Weber","year":"2021","unstructured":"Weber JS, Muramatsu T, Hamid O, Mehnert J, Hodi FS, Krishnarajapet S, Malatyali S, Buchbinder E, Goldberg J, Sullivan R, Faries M, Mehmi I (2021) Mehmi Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma. Ann Oncol 32(Suppl_5):S867\u2013S905. https:\/\/doi.org\/10.1016\/annonc\/annonc706","journal-title":"Ann Oncol"},{"key":"3850_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632\u2013634. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x","journal-title":"J Thromb Haemost"},{"key":"3850_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","volume":"196","author":"C Solinas","year":"2020","unstructured":"Solinas C, Saba L, Sganzerla P et al (2020) Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review. Thromb Res 196:444\u2013453. https:\/\/doi.org\/10.1016\/j.thromres.2020.09.038","journal-title":"Thromb Res"},{"key":"3850_CR25","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik F, Chan W-SE, Wiedemann S et al (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137:1669\u20131678. https:\/\/doi.org\/10.1182\/blood.2020007878","journal-title":"Blood"},{"key":"3850_CR26","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.3390\/curroncol30030230","volume":"30","author":"T-F Wang","year":"2023","unstructured":"Wang T-F, Carrier M (2023) Immune checkpoint inhibitors-associated thrombosis: incidence, risk factors and management. Curr Oncol 30:3032\u20133046. https:\/\/doi.org\/10.3390\/curroncol30030230","journal-title":"Curr Oncol"},{"key":"3850_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","volume":"2","author":"J Roopkumar","year":"2021","unstructured":"Roopkumar J, Swaidani S, Kim AS et al (2021) Increased incidence of venous thromboembolism with cancer immunotherapy. Med (N Y) 2:423\u2013434. https:\/\/doi.org\/10.1016\/j.medj.2021.02.002","journal-title":"Med (N Y)"},{"key":"3850_CR28","first-page":"1","volume":"28","author":"Q-Y Zhang","year":"2018","unstructured":"Zhang Q-Y, Crist J (2018) Ivers T performance comparison of two sysmex hematology analyzers: the XN-550 and the XS-1000i. Sysmex J Int 28:1\u201312","journal-title":"Sysmex J Int"},{"key":"3850_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/MBC.0b013e32834a7e01","volume":"22","author":"EJ Favaloro","year":"2011","unstructured":"Favaloro EJ (2011) Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 22:553\u2013564. https:\/\/doi.org\/10.1097\/MBC.0b013e32834a7e01","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3850_CR30","unstructured":"Weiss D, Achenbach S, Zimmermann R (2022) Special coagulation history questionnaire [German]. https:\/\/www.transfusionsmedizin.uk-erlangen.de\/fileadmin\/einrichtungen\/transfusionsmedizin\/dateien\/Unterlagen_gesamt_Sprechstunden_02.pdf. Accessed 24 Oct 2023"},{"key":"3850_CR31","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1055\/s-0042-1749185","volume":"122","author":"Z Ma","year":"2022","unstructured":"Ma Z, Sun X, Zhang Y et al (2022) Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials. Thromb Haemost 122:1757\u20131766. https:\/\/doi.org\/10.1055\/s-0042-1749185","journal-title":"Thromb Haemost"},{"key":"3850_CR32","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2022-160087","volume":"140","author":"F Moik","year":"2022","unstructured":"Moik F, Riedl J, Barth D et al (2022) Early dynamics of C-reactive protein predict risk of venous thromboembolism in patients with cancer treated with immune checkpoint inhibitors. Blood 140:1250\u20131251. https:\/\/doi.org\/10.1182\/blood-2022-160087","journal-title":"Blood"},{"key":"3850_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001564","author":"S Fukuda","year":"2021","unstructured":"Fukuda S, Saito K, Yasuda Y et al (2021) Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001564","journal-title":"J Immunother Cancer"},{"key":"3850_CR34","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","volume":"145","author":"A-R Abolhassani","year":"2019","unstructured":"Abolhassani A-R, Schuler G, Kirchberger MC et al (2019) C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol 145:2625\u20132631. https:\/\/doi.org\/10.1007\/s00432-019-03002-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"3850_CR35","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","volume":"147","author":"B Husain","year":"2021","unstructured":"Husain B, Kirchberger MC, Erdmann M et al (2021) Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol 147:1623\u20131630. https:\/\/doi.org\/10.1007\/s00432-021-03550-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"3850_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/archinte.158.6.585","volume":"158","author":"MD Silverstein","year":"1998","unstructured":"Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585\u2013593. https:\/\/doi.org\/10.1001\/archinte.158.6.585","journal-title":"Arch Intern Med"},{"key":"3850_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s0140-6736(95)90166-3","volume":"345","author":"T Koster","year":"1995","unstructured":"Koster T, Blann AD, Bri\u00ebt E et al (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152\u2013155. https:\/\/doi.org\/10.1016\/s0140-6736(95)90166-3","journal-title":"Lancet"},{"key":"3850_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.seminhematol.2004.09.009","volume":"42","author":"I Martinelli","year":"2005","unstructured":"Martinelli I (2005) von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42:49\u201355. https:\/\/doi.org\/10.1053\/j.seminhematol.2004.09.009","journal-title":"Semin Hematol"},{"key":"3850_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jth.14343","volume":"17","author":"IM Rietveld","year":"2019","unstructured":"Rietveld IM, Lijfering WM, Le Cessie S et al (2019) High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost 17:99\u2013109. https:\/\/doi.org\/10.1111\/jth.14343","journal-title":"J Thromb Haemost"},{"key":"3850_CR40","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/jth.15611","volume":"20","author":"GE Walker","year":"2022","unstructured":"Walker GE, Merlin S, Zanolini D et al (2022) Factor VIII as a potential player in cancer pathophysiology. J Thromb Haemost 20:648\u2013660. https:\/\/doi.org\/10.1111\/jth.15611","journal-title":"J Thromb Haemost"},{"key":"3850_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006456","author":"J-C Stadler","year":"2023","unstructured":"Stadler J-C, Keller L, Mess C et al (2023) Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-006456","journal-title":"J Immunother Cancer"},{"key":"3850_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12728","volume":"6","author":"R Cantrell","year":"2022","unstructured":"Cantrell R, Palumbo JS (2022) Hemostasis and tumor immunity. Res Pract Thromb Haemost 6:e12728. https:\/\/doi.org\/10.1002\/rth2.12728","journal-title":"Res Pract Thromb Haemost"},{"key":"3850_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2022.152311","volume":"228","author":"J Schl\u00fcter","year":"2023","unstructured":"Schl\u00fcter J, Cunningham S, Zimmermann R et al (2023) Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation. Immunobiology 228:152311. https:\/\/doi.org\/10.1016\/j.imbio.2022.152311","journal-title":"Immunobiology"},{"key":"3850_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw8405","author":"C Graf","year":"2019","unstructured":"Graf C, Wilgenbus P, Pagel S et al (2019) Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aaw8405","journal-title":"Sci Immunol"},{"key":"3850_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205103","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Pemler S et al (2021) Anticoagulation with factor Xa inhibitors is associated with improved overall response and progression-free survival in patients with metastatic malignant melanoma receiving immune checkpoint inhibitors-a retrospective, real-world cohort study. Cancers. https:\/\/doi.org\/10.3390\/cancers13205103","journal-title":"Cancers"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03850-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:48:16Z","timestamp":1738259296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03850-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3850"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03850-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"14 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MB: no conflicts of interest to disclose JS: no conflicts of interest to disclose ME: honoraria and travel support from Bristol Myers Squibb, Immunocore, Novartis, Pierre Fabre and Sanofi, outside the submitted work RK: no conflicts of interest to disclose SC: no conflicts of interest to disclose HH: no conflicts of interest to disclose RZ: Lecture fees from CSL, Stago and Siemens, outside the submitted work LH: consultancy\/ad boards BiomeDx, BMS, Immunocore, MSD, Merck, Roche, Amgen, Curevac, Novartis, Sanofi, SUN, Pierre Fabre, Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of University of Erlangen (approval #82_19B, 20.03.2019; Amendment: 26.11.2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}},{"value":"Written informed consent has been obtained from the patients to publish this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to publish"}}],"article-number":"5"}}